Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care
Keyword(s):
ABSTRACT In India and China, indigenous drug manufacturers market arbitrarily combined parenteral β-lactam and β-lactamase inhibitors (BL-BLIs). In these fixed-dose combinations, sulbactam or tazobactam is indiscriminately combined with parenteral cephalosporins, with BLI doses kept in ratios similar to those for the approved BL-BLIs. Such combinations have been introduced into clinical practice without mandatory drug development studies involving pharmacokinetic/pharmacodynamic, safety, and efficacy assessments being undertaken. Such unorthodox combinations compromise clinical outcomes and also potentially contribute to resistance development.
Keyword(s):
2020 ◽
Vol 6
(2)
◽
pp. 140-142
2011 ◽
Vol 20
(4)
◽
pp. 121-123
2020 ◽
Vol 155
(2)
◽
2020 ◽
Vol 41
(5)
◽
pp. 604-607
◽
2020 ◽
Vol 7
(Supplement_1)
◽
pp. S116-S116
Keyword(s):
2020 ◽
Vol 7
(Supplement_1)
◽
pp. S69-S70